Daiichi Seeks To Stall Singh Asset Sales In Ranbaxy Compensation Battle
Executive Summary
Daiichi Sankyo has chalked up a procedural win in its ongoing court battle for compensation from Indian tycoons Malvinder and Shivinder Singh over the Japanese company’s ill-fated acquisition of Indian generic giant Ranbaxy.
You may also be interested in...
Daiichi Closing Indian Site As Global Restructuring Continues
Daiichi Sankyo's decision to close an R&D facility in India has drawn mixed responses from the local industry, coming as it does against the backdrop of the Japanese firm’s disastrous acquisition of Ranbaxy.
Analysts Cut Sun Forecasts After New Halol Site Faults
Analysts are cutting back profit forecasts for Indian generic giant Sun Pharma after the US FDA detailed a host of new testing and quality control issues at the company’s key Halol factory.
Golden Week For Daiichi: Damages Due From Ranbaxy Brothers
In what seems like some consolation for Daiichi Sankyo after its disastrous acquisition of Ranbaxy Laboratories and subsequent divestment of the Indian company, arbitration proceedings in Singapore against the Singh brothers of Ranbaxy have gone the Japanese firm's way.